TREATMENT
Phase 1 trial evaluates oral KRAS G12D inhibitor GFH375 in advanced solid tumorsA phase 1 dose-escalation trial evaluated GFH375, an oral compound that targets both active and inactive states of KRAS G12D proteins, in patients with advanced solid tumors harboring the KRAS G12D mutation, including colorectal cancer. (Nat Med)